Financial reports
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
13 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
10 May 19
10-K
2018 FY
Annual report
18 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
Current reports
8-K
Aytu BioScience Announces Close of Merger with Neos Therapeutics
22 Mar 21
8-K
Entry into a Material Definitive Agreement
8 Feb 21
8-K
Corporate Presentation January 2021
11 Jan 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Dec 20
8-K
Entry into a Material Definitive Agreement
11 Dec 20
8-K
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue1 Specialty Pharmaceutical Company
10 Dec 20
8-K
Neos Therapeutics Reports Third Quarter 2020 Financial Results
9 Nov 20
8-K
Neos Therapeutics Reports Second Quarter 2020 Financial Results
10 Aug 20
8-K
Departure of Directors or Certain Officers
19 Jun 20
8-K
Entry into a Material Definitive Agreement
11 Jun 20
Registration and prospectus
15-12B
Securities registration termination
30 Mar 21
425
Business combination disclosure
22 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
10 Feb 21
DEFM14A
Proxy related to merger
9 Feb 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEF 14A
Definitive proxy
21 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 19
DEF 14A
Definitive proxy
24 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
DEFA14A
Additional proxy soliciting materials
28 Apr 17
Other
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
2 May 19
CORRESP
Correspondence with SEC
29 Apr 19
CT ORDER
Confidential treatment order
1 Apr 19
UPLOAD
Letter from SEC
21 Mar 19
EFFECT
Notice of effectiveness
21 Dec 18
CORRESP
Correspondence with SEC
18 Dec 18